Holen Sie sich die Stockscreener-App
5.98
4.32%
-0.27
Vorhandelsmarkt:
5.03
-0.95
-15.89%
Schlusskurs vom Vortag:
$6.25
Offen:
$6.16
24-Stunden-Volumen:
85,917
Relative Volume:
0.76
Marktkapitalisierung:
$255.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.90M
KGV:
-11.28
EPS:
-0.53
Netto-Cashflow:
$-19.80M
1W Leistung:
-2.92%
1M Leistung:
-5.08%
6M Leistung:
+49.50%
1J Leistung:
+111.31%
1-Tages-Spanne:
$5.89
$6.20
1-Wochen-Bereich:
$5.75
$6.8184
52-Wochen-Spanne:
$2.14
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Vergleichen Sie DMAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
5.98 | 255.71M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
DiaMedica Therapeutics Appoints Daniel J. O’Connor to Board - MSN
DiaMedica welcomes new board member with biopharma leadershi By Investing.com - Investing.com Nigeria
DiaMedica welcomes new board member with biopharma leadershi - Investing.com
Can This Biotech Leader Who Turned $40M into $2B Transform DiaMedica Next? - StockTitan
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 8.4% - MarketBeat
DiaMedica reports on DM199 stroke treatment mechanism By Investing.com - Investing.com Nigeria
DiaMedica reports on DM199 stroke treatment mechanism - Investing.com
DiaMedica Therapeutics Announces Publication Of Dm199'S Mechanism Of Action For The Treatment Of Acute Ischemic Stroke In The Journal Stroke - Marketscreener.com
Revolutionary Stroke Treatment Mechanism Revealed: How DM199 Could Transform Patient Care - StockTitan
Learn to Evaluate (DMAC) using the Charts - Stock Traders Daily
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
DiaMedica's Game-Changing Stroke Treatment Takes Center Stage at Major Healthcare Conference (DMAC) - StockTitan
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 14.5% - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Here's Why - MarketBeat
DiaMedica Therapeutics: Interesting Work In Treating Ischemic Stroke - Seeking Alpha
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$43m - Simply Wall St
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December - Defense World
Diamedica Stock Soars to 52-Week High, Hits $6.41 - Investing.com
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m - Yahoo Finance
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 12.2% - MarketBeat
Diamedica Stock Soars to 52-Week High, Reaching $5.74 - Investing.com
Diamedica Stock Soars to 52-Week High, Reaching $5.74 By Investing.com - Investing.com UK
DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% HigherHere's What Happened - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% Higher – Should You Buy? - Defense World
Amneal to Participate at Upcoming Investor Conferences - Business Wire
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia - BioSpace
DiaMedica Therapeutics management to meet virtually with Lake Street - Nasdaq
DiaMedica Forms Elite Scientific Advisory Board for Preeclampsia Treatment Development - StockTitan
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition - Business Wire
DMAC Stock Soars to 52-Week High, Hits $4.95 Amid Bullish Run - Investing.com
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation - Simply Wall St
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks
DMACDiaMedica Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - BioSpace
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - BioSpace
DiaMedica (DMAC) to Present at Craig-Hallum Conference: Spotlight on DM199 Stroke Treatment | DMAC Stock News - StockTitan
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Yahoo Finance
DiaMedica Therapeutics (DMAC) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
CRH plc (the "Company") Form 10-Q for the quarterly period ended September 30, 2024 - Business Wire
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - BioSpace
Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):